The announcement of positive clinical data is likely to boost investor confidence in Quoin Pharmaceuticals, as it demonstrates the potential effectiveness of QRX003 in treating Netherton Syndrome. The absence of adverse events further strengthens the positive outlook, potentially leading to a short-term increase in stock price.